Willy Quinn, CEO of Bullet Biotechnology

Prior to founding Bullet Bio, Willie was one of the first employees at Jazz Pharmaceuticals, where he worked for more than 8 years. As head of Corporate Development, his role included strategy development and execution, helping Jazz transform from a raw startup to a profitable, public specialty pharma company. Before Jazz, Willie was CFO and COO at Novation Biosciences, a biotech software company acquired by Agilent Technologies.

Willie's passion for Life Sciences developed while he was an Associate Partner at Mobius Venture Capital, making investments from two funds totaling over $2.1 billion and managing a portfolio that grew to include 12 companies. He endeavors to help translational medicine by serving as an Advisor to Stanford’s SPARK program and UCSF’s T1 Catalyst Program.

Willie is a Director of Midnight Pharmaceuticals, Neurogastrx, and A Foundation Building Strength, a non-profit finding treatments for Nemaline Myopathy.

Willie received an MBA, an MA, and a BA from Stanford University.

Related Media